Compare KWY & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KWY | OABI |
|---|---|---|
| Founded | N/A | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.1M | 294.3M |
| IPO Year | 2013 | 2021 |
| Metric | KWY | OABI |
|---|---|---|
| Price | $9.72 | $4.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 45.3K | ★ 2.1M |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.56 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $134,996,000.00 | $18,666,000.00 |
| Revenue This Year | N/A | $52.42 |
| Revenue Next Year | N/A | $64.69 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 23.42 | N/A |
| 52 Week Low | $8.41 | $1.32 |
| 52 Week High | $11.36 | $5.43 |
| Indicator | KWY | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 43.15 | 51.56 |
| Support Level | $8.58 | $1.71 |
| Resistance Level | $9.60 | $5.43 |
| Average True Range (ATR) | 0.35 | 0.33 |
| MACD | -0.08 | -0.13 |
| Stochastic Oscillator | 1.51 | 4.28 |
Kingsway Corp is a U.S.-based company employing the Search Fund model to acquire and build great businesses. The company owns and operates a collection of B2B and B2C services companies that are asset-light, growing, profitable, and that have recurring revenues. It seeks to compound long-term shareholder value on a per share basis via its decentralized management model, its talented team of operators, and its tax-advantaged corporate structure.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.